Sophiris Bio Inc (SPHS) Stocks under pressure after Urinary Tract Drug returns negative result in Phase 3 testing

December 15, 2014 4:50 PM

3 0

Sophiris Bio Inc (NASDAQ:SPHS) announced bad news from the Phase 3 study of its urinary tract drug known as PRX302. The company said that interim data from the trial of the drug seemed to raise questions about the drug’s efficacy. Specifically, the drug failed to return positive results in the treatment of enlarged prostate, according to a report.

Although the interim data appeared to pour cold water on commercialization hopes regarding PRX302, the company said all was not lost. It said that it would continue with the ongoing Phase 3 trial and have the final analysis later in 2015. Additionally, other sources have cited that Sophiris Bio Inc ...

Read more

To category page